Dr. Andre Goy on Future Treatments for Patients With Diffuse Large B-Cell Lymphoma
Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).
Andre Goy, MD, MS, chief, John Theurer Cancer Center Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).
Goy says that some of the upcoming novel agents showing promise are bortezomib, both as a single agent and in conjunction with R-CHOP chemotherapy, as well as ibrutinib. Both ibrutinib and bortezomib showed great promise in phase II clinical trials and will be going on to phase III trials to determine their viability as treatments.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
